REGN
REGN
Regeneron Pharmaceuticals, Inc.
$654.27
+$29.55 (+4.73%)
Mkt Cap: $67.40B
Home / REGN / News

Regeneron Pharmaceuticals, Inc. (REGN) News

earnings

Double-Digit Revenue Expansion: Pipeline Milestones Fuel Growth (REGN Q1 2026 Earnings Call)

Regeneron achieved double-digit revenue growth in the first quarter of 2026, demonstrating how strong commercial execution across core franchises can successfully fund next-generation pipeline development. The company reported strong performance from key growth products, updated gross margin guidance due to a temporary Limerick manufacturing halt, and celebrated a historic first gene therapy approval.